• Mangalam Drugs board meeting scheduled for May 14, 2026 to approve audited financial results for Q4 and FY ending March 31, 2026.
• Trading window closed from April 1, 2026 until 48 hours after results announcement per insider trading regulations.
• Disclosure made pursuant to SEBI Listing Obligations & Disclosure Requirements Regulation 29.